title: Should a booster dose be administered in children after mass immunization for hepatitis B?
abstract: BACKGROUND
  Hepatitis B virus infection is a global health problem and vaccine-preventable disease, but the duration of the effects of HBV vaccination in infants is unknown.
  
  
  OBJECTIVE
  The aim of this trial, which comprised children who had received 3 doses as part of the universal HBV immunization program and no additional doses, was to investigate anti-HBs titers and HBsAg status after 9 years.
  
  
  METHODS
  We performed a descriptive, cross-sectional field research study. The study sample, based on sociodemographics and minimum seroprevalence, was analyzed based on 10.00% ± 1.50 (95% confidence interval) (1150 individuals); trial was realized in a total of 1279 children (623 females and 656 males). Anti-HBs titers were measured by micro-EIA (Dia Sorin-Italy); titers < 10 IU/mL were negative, 10-49 IU/mL were low-positive, and > 50 IU/mL were high-positive. For anti-HBs titers below protective levels, HBsAg was measured by micro-EIA.
  
  
  RESULTS
  In approximately half of the children (48.5% in those living in semiurban areas and 42.3% in urban areas), antibody titers were below protective levels.
  
  
  CONCLUSIONS
  Mass HBV vaccination, which was implemented in Turkey in 1998, significantly decreases HBsAg positivity in childhood. Nevertheless, it might be necessary to administer a booster dose after 8-9 years in children, especially those in low socioeconomic areas or in whom irregular/insufficient immunization is suspected.
authors.affiliation: Manisa State Hospital, Department of Infectious Diseases and Clinical Microbiology, Manisa, Turkey.
authors.forename: Selma
authors.initials: S
authors.lastname: Tosun
authors.forename: Serol
authors.initials: S
authors.lastname: Deveci
authors.forename: Yunus
authors.initials: Y
authors.lastname: Kaplan
authors.forename: Erhun
authors.initials: E
authors.lastname: Kasirga
references.citation: Lancet. 2000 Feb 12;355(9203):561-5
references.pmid: 10683019
references.citation: Vaccine. 2000 Nov 22;19(7-8):877-85
references.pmid: 11115711
references.citation: J Viral Hepat. 2004 Mar;11(2):97-107
references.pmid: 14996343
references.citation: Pediatr Infect Dis J. 2003 Feb;22(2):157-63
references.pmid: 12586980
references.citation: Vaccine. 2007 Apr 30;25(17):3511-4
references.pmid: 17400337
references.citation: MMWR Recomm Rep. 1991 Nov 22;40(RR-13):1-25
references.pmid: 1835756
references.citation: Pediatr Infect Dis J. 2004 Jul;23(7):650-5
references.pmid: 15247604
references.citation: Cancer. 1989 Dec 1;64(11):2377-80
references.pmid: 2553245
references.citation: J Med Virol. 2007 Feb;79(2):138-43
references.pmid: 17177303
references.citation: East Mediterr Health J. 2005 Jan-Mar;11(1-2):62-7
references.pmid: 16532672
references.citation: Vaccine. 2001 Apr 6;19(20-22):2812-8
references.pmid: 11282191
references.citation: Vaccine. 2010 Jan 8;28(3):623-31
references.pmid: 19887132
references.citation: J Infect Dis. 1999 Jun;179(6):1319-25
references.pmid: 10228050
references.citation: J Gastrointestin Liver Dis. 2007 Dec;16(4):403-6
references.pmid: 18193122